Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis.

Eric D ShahLin ChangAnthony LemboKyle StallerMichael A CurleyWilliam D Chey

Published in: Digestive diseases and sciences (2021)

Broader prescription drug coverage for patients failing common, inexpensive IBS treatments to which at least 30-40% of patients would typically respond appears warranted to enable gastroenterologists to offer personalized approaches targeting specific mechanisms of this heterogeneous disease.

Keyphrases

end stage renal disease
irritable bowel syndrome
ejection fraction
newly diagnosed
peritoneal dialysis
cancer therapy